NEW YORK, March 27, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of ISTA Pharmaceuticals, Inc. ("ISTA" or the "Company") (NASDAQ: ISTA) concerning the proposed acquisition of the Company by Bausch & Lomb in a transaction valued at approximately $500 million.
(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )
On March 27, 2012, it was announced that ISTA and Bausch & Lomb have entered into a definitive agreement pursuant to which Bausch & Lomb will acquire ISTA. Under the agreement, ISTA shareholders will receive $9.10 in cash per share held. At least one analyst has set a target price for ISTA stock of $12.00 per share.
Our investigation concerns whether the board of directors is fulfilling its fiduciary duties, maximizing the value of ISTA, disclosing all material benefits and costs and obtaining full and fair consideration for ISTA shareholders.
If you own ISTA shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP